Biophytis S.A. (ALBPS.PA)
EUR 0.33
(0.92%)
EUR 0.33
(0.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 15.84 Million EUR | -33.68% |
| 2022 | 23.89 Million EUR | -21.79% |
| 2021 | 30.55 Million EUR | 49.95% |
| 2020 | 20.37 Million EUR | -19.13% |
| 2019 | 25.19 Million EUR | 69.61% |
| 2018 | 14.85 Million EUR | 212.04% |
| 2017 | 4.76 Million EUR | 22.9% |
| 2016 | 3.87 Million EUR | 109.34% |
| 2015 | 1.85 Million EUR | 22.09% |
| 2014 | 1.51 Million EUR | 46.15% |
| 2013 | 1.03 Million EUR | -4.36% |
| 2012 | 1.08 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 15.13 Million EUR | 0.0% |
| 2024 Q1 | 15.13 Million EUR | -4.52% |
| 2023 FY | 15.84 Million EUR | -33.68% |
| 2023 Q1 | 17.96 Million EUR | -24.82% |
| 2023 Q2 | 17.96 Million EUR | 0.0% |
| 2023 Q4 | 15.84 Million EUR | 0.0% |
| 2023 Q3 | 15.84 Million EUR | -11.79% |
| 2022 Q2 | 30.92 Million EUR | 0.0% |
| 2022 Q4 | 23.89 Million EUR | 0.0% |
| 2022 FY | 23.89 Million EUR | -21.79% |
| 2022 Q3 | 23.89 Million EUR | -22.72% |
| 2022 Q1 | 30.92 Million EUR | 1.2% |
| 2021 Q3 | 29.06 Million EUR | -2.35% |
| 2021 FY | 30.55 Million EUR | 49.95% |
| 2021 Q1 | 29.76 Million EUR | 46.08% |
| 2021 Q2 | 29.76 Million EUR | 0.0% |
| 2021 Q4 | 30.55 Million EUR | 5.12% |
| 2020 Q3 | 24.94 Million EUR | 7.11% |
| 2020 Q1 | 23.28 Million EUR | -7.59% |
| 2020 Q2 | 23.28 Million EUR | 0.0% |
| 2020 Q4 | 20.37 Million EUR | -18.3% |
| 2020 FY | 20.37 Million EUR | -19.13% |
| 2019 FY | 25.19 Million EUR | 69.61% |
| 2019 Q3 | 25.95 Million EUR | 48.64% |
| 2019 Q1 | 17.06 Million EUR | 14.86% |
| 2019 Q4 | 25.19 Million EUR | -2.92% |
| 2019 Q2 | 17.46 Million EUR | 2.34% |
| 2018 Q4 | 14.85 Million EUR | 0.0% |
| 2018 FY | 14.85 Million EUR | 212.04% |
| 2018 Q3 | 14.85 Million EUR | 163.64% |
| 2018 Q2 | 5.63 Million EUR | 0.0% |
| 2018 Q1 | - EUR | -100.0% |
| 2017 Q4 | 4.76 Million EUR | 0.04% |
| 2017 FY | 4.76 Million EUR | 22.9% |
| 2017 Q1 | 3.27 Million EUR | -15.59% |
| 2017 Q2 | 3.27 Million EUR | 0.0% |
| 2017 Q3 | 4.75 Million EUR | 45.54% |
| 2016 Q1 | 2.93 Million EUR | 58.71% |
| 2016 Q4 | 3.87 Million EUR | 0.0% |
| 2016 FY | 3.87 Million EUR | 109.34% |
| 2016 Q3 | 3.87 Million EUR | 31.95% |
| 2016 Q2 | 2.93 Million EUR | -0.03% |
| 2015 Q3 | 1.94 Million EUR | -52.5% |
| 2015 Q1 | 4.09 Million EUR | 170.01% |
| 2015 FY | 1.85 Million EUR | 22.09% |
| 2015 Q4 | 1.85 Million EUR | -4.81% |
| 2015 Q2 | 4.09 Million EUR | 0.0% |
| 2014 Q3 | 1.51 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q4 | 1.51 Million EUR | 0.0% |
| 2014 FY | 1.51 Million EUR | 46.15% |
| 2013 FY | 1.03 Million EUR | -4.36% |
| 2012 FY | 1.08 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -129.297% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 87.906% |
| Adocia SA | 31.87 Million EUR | 50.27% |
| Aelis Farma SA | 13.08 Million EUR | -21.17% |
| Advicenne S.A. | 24.37 Million EUR | 34.984% |
| genOway Société anonyme | 14.45 Million EUR | -9.61% |
| IntegraGen SA | 5.97 Million EUR | -165.042% |
| Medesis Pharma S.A. | 6.42 Million EUR | -146.632% |
| Neovacs S.A. | 3.71 Million EUR | -326.952% |
| NFL Biosciences SA | 3.62 Million EUR | -337.735% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -133.68% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -378.806% |
| Sensorion SA | 13.22 Million EUR | -19.821% |
| Theranexus Société Anonyme | 5.01 Million EUR | -215.957% |
| TME Pharma N.V. | 2.78 Million EUR | -469.084% |
| Valbiotis SA | 13.7 Million EUR | -15.619% |
| TheraVet SA | 1.48 Million EUR | -967.278% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 22.567% |
| argenx SE | 402.79 Million EUR | 96.065% |
| BioSenic S.A. | 32.26 Million EUR | 50.877% |
| Celyad Oncology SA | 9.97 Million EUR | -58.839% |
| DBV Technologies S.A. | 38.74 Million USD | 59.094% |
| Galapagos NV | 1.56 Billion EUR | 98.985% |
| Genfit S.A. | 105.92 Million EUR | 85.037% |
| GeNeuro SA | 20.13 Million EUR | 21.305% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -84.034% |
| Innate Pharma S.A. | 132.29 Million EUR | 88.02% |
| Inventiva S.A. | 101.59 Million EUR | 84.4% |
| MaaT Pharma SA | 22.46 Million EUR | 29.45% |
| MedinCell S.A. | 77.77 Million EUR | 79.621% |
| Nanobiotix S.A. | 95.74 Million EUR | 83.446% |
| Onward Medical N.V. | 25.69 Million EUR | 38.326% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 36.921% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 73.173% |
| Oxurion NV | 19.73 Million EUR | 19.695% |
| Pharming Group N.V. | 228.28 Million EUR | 93.057% |
| Poxel S.A. | 53.9 Million EUR | 70.596% |
| GenSight Biologics S.A. | 34.72 Million EUR | 54.361% |
| Transgene SA | 26.51 Million EUR | 40.231% |
| Financière de Tubize SA | 123.65 Million EUR | 87.182% |
| UCB SA | 6.56 Billion EUR | 99.759% |
| Valneva SE | 341.14 Million EUR | 95.354% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -248.559% |